Geon(TM) MB3040 Black Filter GEON L7002 LHB ADOBE X44 3689 (T?) PP FR 8-6 LMS-1000

SILCOPAS BLACK Geon(TM) SP103-70 JH Closure FG PP FR 8-6 LMS-1000

70-BK-121 BLACK RC BLACK AO PP FR 8-6 LMS-1000

RUGER BLACK NY VERSALLOY(TM)HC 9220-70 NATURAL PP FR 8-6 LMS-1000

BLACK PE CORE(TM) AM100 PURPLE HH-70 (WABASH) PP FR 8-6 LMS-1000

MB2483A BLACK 70 TYPE 5B8A-CHARCOAL BLACK/7710 PP FR 8-6 LMS-1000

X80000700901 Black Geon(TM) MB2490A 70 Black LC PP FR 8-6 LMS-1000

3001-BN-70 BN STD PA 6-12 MASTERBATCH BLACK BASE PP FR 8-6 LMS-1000

GEON B7500 BLACK V1466-70 WHITE PP FR 8-6 LMS-1000

Microsoft PowerPoint - Avient March IR - Fermium AVIENT CORPORATION (NYSE: AVNT) M A R C H 1 8 , 2 0 2 1 I R M E E T I N G S H O S T E D B Y F E R M I U M R E S E A R C H DISCLAIMER 2 Forward-Looking Statements In this presentation, statements that are not reported financial results or other historical information are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. D is t. ) K W R R P M P P G A V Y F U L G C P F M C H X L IF F F O E H U N E C L K R A E M N A S H C E S C L G R A A LB Median: 5%Median: 3% Source: Peer data per Bloomberg market data as of March 12, 2021 Avient reflects 2021 estimated revenue of $4,100M and excludes one-time synergy capture CAPEX ($20M) Avient Specialty Formulators Other Chemical/Specialty Companies Free Cash Flow Conversion (1) 2021E (%) Being asset light helps us to generate strong free cash flow that is in line with specialty formulators. Free cash flow conversion calculated as (EBITDA – Capex) / EBITDA Median: 84% Median: 77% HIGH FREE CASH FLOW CONVERSION Avient reflects 2021 estimated EBITDA of $510M and excludes one-time synergy capture CAPEX ($20M) Source: Peer data per Bloomberg market data as of March 12, 2021 85 89 86 86 82 80 76 89 85 83 82 81 78 77 77 76 75 73 70 69 49 19 A vi en t K W R P P G R P M A V Y F U L G C P F M C IF F H X L U N V R E C L A S H B N R F O E E M N C E G R A H U N K R A S C L A L B Source: Peer data per Bloomberg market data as of March 12, 2021 Total Enterprise Value / 2021E EBITDA Our current valuation implies an EBITDA multiple that is below specialty formulator peers and some of our more highly valued chemical peers.